Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

Blood (2009) 113 (20): 4841–4852.

https://doi.org/10.1182/blood-2008-08-172726

Published: 2009

Includes: Supplemental data

Journal Articles

In Vivo Correlates of Response for Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults Age ≥ 70 with Newly Diagnosed Acute Myelogenous Leukemia (AML) Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

Rebecca M. Ricklis, MS, Judith E. Karp, MD, Eric J. Feldman, MD, Suzanne Galkin, BA, Jacqueline M. Greer, RN, Valerie Ironside, CRNP, Kim Mirjafary, Timothy D. Talbot, BA, Lawrence E. Morris, MD, John J. Wright, MD, PhD, Scott H. Kaufmann, MD, PhD

Blood (2007) 110 (11): 914.

https://doi.org/10.1182/blood.V110.11.914.914

Published: 2007

Journal Articles

A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias

Judith E. Karp, Rebecca M. Ricklis, Kumudha Balakrishnan, Janet Briel, Jacqueline Greer, Steven D. Gore, B. Douglas Smith, Michael A. McDevitt, Hetty Carraway, Mark J. Levis, Varsha Gandhi

Blood (2007) 110 (6): 1762–1769.

https://doi.org/10.1182/blood-2007-03-081364

Published: 2007

Journal Articles

Phase I Clinical-Laboratory Trial of Clofarabine (CLO) Followed by Cyclophosphamide (CY) for Adults with Refractory Acute Leukemias: Evidence for Enhanced DNA Damage.

Judith E. Karp, MD, Rebecca M. Ricklis, MBA, Jacqueline Greer, RN, Janet Briel, RN, Mark J. Levis, MD,PhD

Blood (2006) 108 (11): 1963.

https://doi.org/10.1182/blood.V108.11.1963.1963

Published: 2006

Journal Articles

Structure-function analysis of the antioxidant properties of haptoglobin

Meira Melamed-Frank, Orit Lache, Benjamin I. Enav, Tal Szafranek, Nina S. Levy, Rebecca M. Ricklis, Andrew P. Levy

Blood (2001) 98 (13): 3693–3698.

https://doi.org/10.1182/blood.V98.13.3693

Published: 2001

NARROW

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

In Vivo Correlates of Response for Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults Age ≥ 70 with Newly Diagnosed Acute Myelogenous Leukemia (AML) Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias

Phase I Clinical-Laboratory Trial of Clofarabine (CLO) Followed by Cyclophosphamide (CY) for Adults with Refractory Acute Leukemias: Evidence for Enhanced DNA Damage.

Structure-function analysis of the antioxidant properties of haptoglobin

Email alerts

ASH Publications

American Society of Hematology

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

In Vivo Correlates of Response for Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults Age ≥ 70 with Newly Diagnosed Acute Myelogenous Leukemia (AML) Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias

Phase I Clinical-Laboratory Trial of Clofarabine (CLO) Followed by Cyclophosphamide (CY) for Adults with Refractory Acute Leukemias: Evidence for Enhanced DNA Damage.

Structure-function analysis of the antioxidant properties of haptoglobin

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only